Consensus Novavax, Inc.

Stocks

NVAX

US6700024010

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-09-18 EDT			5-day change	1st Jan Change
10.11 ^USD	+1.10%		+8.71%	+50.45%

09-10	Novavax, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-10-2026 10:00 AM
09-09	Novavax, Inc. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-09-2026 09:45 AM

Evolution of the Average Target: Novavax, Inc.

Evolution of the Target Price: Novavax, Inc.

Changes in Analyst Recommendations: Novavax, Inc.

e62bf0ee4249f0fc03b34bc03c2f4.3EQddiShYU5YK51OoJ4egRvE6_VPAEPVLycHmDV-hes.6iFMIhGZEgM1QdoD4a9JsiuepZsaYhSATUY3_WIcxo3pBmgiXtkDKjBH9g~b00520670a5152783e326032fe3a18d2

Analysts' recommendations: Novavax, Inc.

04-09	B. Riley Raises Price Target on Novavax to $18 from $16, Keeps Buy Rating	MT
11-11	B. Riley Adjusts Price Target on Novavax to $16 From $18, Maintains Buy Rating	MT
11-10	B. Riley Adjusts Price Target on Novavax to $16 From $18, Maintains Buy Rating	MT
25-08-20	Novavax: BofA downgrades stock
25-08-20	Novavax Faces 'Increasingly Murky' Outlook on Vaccine Uncertainties, BofA Securities Says	MT
25-08-20	BofA Downgrades Novavax to Underperform From Neutral, Adjusts Price Target to $7 From $9	MT
25-08-20	BofA Securities Downgrades Novavax to Underperform From Neutral, Price Target is $7	MT
25-05-05	B. Riley Cuts Price Target on Novavax to $18 From $22, Keeps Buy Rating	MT
25-02-28	BTIG Initiates Novavax at Buy With $19 Price Target	MT
24-11-18	B. Riley Adjusts Novavax Price Target to $22 From $26, Maintains Buy Rating	MT
24-10-16	Jefferies Cuts Novavax's Price Target to $25 From $31, Buy Rating Maintained	MT
24-10-10	B. Riley Raises Price Target on Novavax to $26 From $23, Keeps Buy Rating	MT
24-08-12	B. Riley Adjusts Price Target on Novavax to $23 From $25, Maintains Buy Rating	MT
24-08-02	B. Riley Adjusts Price Target on Novavax to $25 From $29, Maintain Buy Rating	MT
24-07-30	Novavax Shares Sink After JPMorgan Downgrades Rating to Underweight From Neutral	MT
24-07-30	JPMorgan Downgrades Novavax to Underweight From Neutral, Adjusts Price Target to $8	MT
24-05-23	B. Riley Boosts Price Target on Novavax to $29 From $11, Maintains Buy Rating	MT
24-03-01	HC Wainwright Cuts Price Target on Novavax to $19 From $35, Keeps Buy Rating	MT
24-02-23	B. Riley Trims Novavax's PT to $11 From $12 After Reaching Settlement on Gavi Arbitration Dispute, Keeps Buy Rating	MT
23-12-14	Novavax: green light for updated Covid vaccine in Sweden
23-11-10	B. Riley Lowers Novavax's Price Target to $12 From $15 After Near-Term COVID-19 Sales Estimate Revisions, Maintains Buy Rating	MT
23-08-09	B. Riley Upgrades Novavax to Buy From Neutral After Above-Consensus Q2 Beat, Says Turnaround Progressing; Retains $15 PT	MT
23-05-10	B. Riley Raises Novavax's PT to $15 From $10, Says Q1 Financial Update 'Not As Bad As Feared'; Keeps Neutral Rating	MT
23-03-01	B. Riley Downgrades Novavax to Neutral From Buy, Lowers Price Target to $10 From $29	MT
23-02-17	B. Riley Cuts Novavax's Price Target to $29 From $37, Maintains Buy Rating	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	NOVAVAX, INC.					+40.02%
	LONZA GROUP AG					+26.27%
	IQVIA HOLDINGS INC.					+3.16%
	REVOLUTION MEDICINES, INC.					+27.56%
	BEONE MEDICINES AG					+22.45%
	CELLTRION, INC.					+49.02%
	MEDPACE HOLDINGS, INC.					-5.42%
	ASCENDIS PHARMA A/S					+30.8%
	EUROFINS SCIENTIFIC SE					-6.03%
	ICON PUBLIC LIMITED COMPANY					+9.18%
	Average					+19.70%
	Weighted average by Cap.					+20.19%